| About TRRUST | Search | Download |
VDR is a Transcription Factor.
1. Targets and Regulators
top
VDR targets
| # | TF | Target | Mode of Regulation | References (PMID) |
|---|---|---|---|---|
| 1 | VDR | AMH | Unknown | 19056816 |
| 2 | VDR | ASAP2 | Unknown | 23999061 |
| 3 | VDR | BGLAP | Unknown | 20227497 |
| 4 | VDR | BHLHE40 | Unknown | 23220548 |
| 5 | VDR | CALB1 | Activation | 1317496 |
| 6 | VDR | CAMP | Unknown | 15985530 |
| 7 | VDR | CD14 | Activation | 16402404 |
| 8 | VDR | CDH1 | Activation | 22213313 |
| 9 | VDR | CDKN1A | Unknown | 23087083 |
| 10 | VDR | CDKN1B | Activation | 16518840 |
| 11 | VDR | CST5 | Activation | 19662683 |
| 12 | VDR | CXCL8 | Activation | 9431991 |
| 13 | VDR | CXCL8 | Unknown | 24250750 |
| 14 | VDR | CYP1A1 | Unknown | 22837390 |
| 15 | VDR | CYP24A1 | Activation | 23463632 |
| 16 | VDR | CYP24A1 | Repression | 9687155 |
| 17 | VDR | CYP24A1 | Unknown | 19244278; 19429444; 21763285 |
| 18 | VDR | CYP3A4 | Unknown | 11723248 |
| 19 | VDR | CYP3A4 | Activation | 12147248; 19712670 |
| 20 | VDR | CYP3A4 | Unknown | 11991950; 15205382; 15358113; 18400206; 22939842 |
| 21 | VDR | CYP3A5 | Unknown | 22939842 |
| 22 | VDR | CYP3A7 | Unknown | 15358113 |
| 23 | VDR | CYP7A1 | Repression | 19106115; 20371703 |
| 24 | VDR | DDIT4 | Unknown | 21123297 |
| 25 | VDR | DKK4 | Repression | 18408752 |
| 26 | VDR | EGFR | Repression | 16087726 |
| 27 | VDR | EGFR | Unknown | 15218361 |
| 28 | VDR | ERBB2 | Unknown | 10765127 |
| 29 | VDR | FOXP3 | Unknown | 22529297 |
| 30 | VDR | HLA-DRB1 | Unknown | 19956544 |
| 31 | VDR | HOXA10 | Activation | 15905361 |
| 32 | VDR | IGFBP3 | Repression | 23770368 |
| 33 | VDR | IGFBP3 | Unknown | 14963110 |
| 34 | VDR | IL10 | Repression | 20691220 |
| 35 | VDR | IL12B | Repression | 21310195 |
| 36 | VDR | IL2 | Repression | 7565732 |
| 37 | VDR | IL6 | Repression | 11050002 |
| 38 | VDR | NCOR1 | Activation | 23098689 |
| 39 | VDR | PHB | Unknown | 16849588; 17207617 |
| 40 | VDR | PLD1 | Unknown | 17433303 |
| 41 | VDR | PODXL | Unknown | 23548800 |
| 42 | VDR | PRL | Unknown | 10406465 |
| 43 | VDR | PTH | Repression | 17095575; 7489414 |
| 44 | VDR | SKP2 | Repression | 16883603 |
| 45 | VDR | TLR10 | Unknown | 24373795 |
| 46 | VDR | TNFRSF21 | Activation | 12520529 |
| 47 | VDR | TPT1 | Activation | 19815065 |
| 48 | VDR | TRPV6 | Unknown | 17293108; 20227497; 22563729 |
| 49 | VDR | UCP1 | Unknown | 23906633 |
Modularity measured by P value : 0.236
TFs that regulate VDR
| # | TF | Target | Mode of Regulation | References (PMID) |
|---|---|---|---|---|
| 1 | CDX2 | VDR | Unknown | 11450701; 16604479; 16883525; 19960008 |
| 2 | EZH2 | VDR | Unknown | 23424038 |
| 3 | JUN | VDR | Activation | 15930183 |
| 4 | KLF4 | VDR | Repression | 22677193 |
| 5 | MED1 | VDR | Unknown | 17229570 |
| 6 | PIAS4 | VDR | Unknown | 22564762 |
| 7 | POU1F1 | VDR | Activation | 17456792 |
| 8 | SMAD3 | VDR | Activation | 17471513 |
| 9 | SNAI1 | VDR | Repression | 15322538; 16804902; 20138990 |
| 10 | SNAI2 | VDR | Repression | 18485278; 20138990 |
| 11 | SNW1 | VDR | Unknown | 15225769 |
| 12 | SP1 | VDR | Unknown | 15664452 |
| 13 | STAT3 | VDR | Repression | 23424038 |
| 14 | TP63 | VDR | Activation | 22521434 |
| 15 | TP63 | VDR | Unknown | 16462763; 17716971 |
| 16 | TP73 | VDR | Unknown | 17716971 |
| 17 | WT1 | VDR | Activation | 23362234 |
| 18 | WT1 | VDR | Unknown | 11050081; 11773605 |
| 19 | ZNF224 | VDR | Activation | 23362234 |
Modularity measured by P value : 0.001
2. Other TFs that share targets with VDR
top
TFs that share targets with VDR
* P values are calculated with hypergeometric test.
| TF | # of overlapped target genes | P value | FDR |
|---|---|---|---|
| HDAC1 | 10 | 7.56e-15 | 2.42e-13 |
| RELA | 14 | 3.59e-14 | 1.02e-12 |
| SP1 | 16 | 5.12e-14 | 1.40e-12 |
| NFKB1 | 13 | 9.01e-13 | 1.96e-11 |
| WT1 | 8 | 1.71e-12 | 3.49e-11 |
| EP300 | 8 | 4.51e-12 | 8.35e-11 |
| FOXP3 | 5 | 7.49e-11 | 1.08e-09 |
| PGR | 6 | 8.07e-11 | 1.15e-09 |
| STAT3 | 9 | 1.76e-10 | 2.34e-09 |
| ZNF300 | 4 | 2.00e-10 | 2.61e-09 |
| ING4 | 5 | 2.82e-10 | 3.53e-09 |
| KLF4 | 6 | 6.84e-10 | 7.52e-09 |
| ESR1 | 7 | 1.07e-09 | 1.12e-08 |
| REL | 5 | 2.44e-09 | 2.30e-08 |
| JUN | 8 | 5.87e-09 | 5.00e-08 |
| SP3 | 7 | 2.04e-08 | 1.48e-07 |
| RXRA | 4 | 1.89e-07 | 1.01e-06 |
| AR | 6 | 2.49e-07 | 1.29e-06 |
| CEBPA | 5 | 3.02e-07 | 1.52e-06 |
| CEBPB | 5 | 6.51e-07 | 2.93e-06 |
| HDAC2 | 4 | 7.85e-07 | 3.43e-06 |
| YBX1 | 4 | 1.20e-06 | 4.87e-06 |
| SMAD3 | 4 | 1.37e-06 | 5.45e-06 |
| ZFP36 | 3 | 1.95e-06 | 7.34e-06 |
| ETS2 | 4 | 1.98e-06 | 7.44e-06 |
| ATF4 | 4 | 2.78e-06 | 9.77e-06 |
| CREB1 | 5 | 3.77e-06 | 1.26e-05 |
| EGR1 | 5 | 3.77e-06 | 1.26e-05 |
| ETS1 | 5 | 4.20e-06 | 1.37e-05 |
| STAT1 | 5 | 4.20e-06 | 1.37e-05 |
| IRF1 | 4 | 9.92e-06 | 2.80e-05 |
| BRCA1 | 4 | 1.65e-05 | 4.20e-05 |
| HDAC4 | 3 | 3.21e-05 | 7.22e-05 |
| TFAP2A | 4 | 3.43e-05 | 7.64e-05 |
| FOXO1 | 3 | 4.11e-05 | 8.79e-05 |
| HDAC3 | 3 | 4.11e-05 | 8.79e-05 |
| MTA1 | 3 | 4.11e-05 | 8.79e-05 |
| PARP1 | 3 | 5.15e-05 | 1.04e-04 |
| CREBBP | 3 | 6.36e-05 | 1.24e-04 |
| DBP | 2 | 6.58e-05 | 1.28e-04 |
| FHL2 | 2 | 6.58e-05 | 1.28e-04 |
| TP53 | 5 | 6.93e-05 | 1.34e-04 |
| JUND | 3 | 9.31e-05 | 1.71e-04 |
| WWP1 | 2 | 9.85e-05 | 1.79e-04 |
| LEF1 | 3 | 1.20e-04 | 2.11e-04 |
| NR3C1 | 3 | 1.30e-04 | 2.26e-04 |
| ILF3 | 2 | 1.38e-04 | 2.36e-04 |
| KLF10 | 2 | 1.38e-04 | 2.36e-04 |
| EZH2 | 3 | 1.64e-04 | 2.73e-04 |
| IRF9 | 2 | 1.83e-04 | 2.99e-04 |
| HNF4A | 3 | 2.31e-04 | 3.62e-04 |
| SMARCA4 | 2 | 2.35e-04 | 3.68e-04 |
| PPARA | 3 | 2.46e-04 | 3.81e-04 |
| HOXB7 | 2 | 2.93e-04 | 4.42e-04 |
| PROX1 | 2 | 2.93e-04 | 4.42e-04 |
| TFAP2C | 2 | 2.93e-04 | 4.42e-04 |
| MYCN | 3 | 2.96e-04 | 4.46e-04 |
| DNMT3A | 2 | 3.58e-04 | 5.21e-04 |
| KLF2 | 2 | 3.58e-04 | 5.21e-04 |
| MEN1 | 2 | 3.58e-04 | 5.21e-04 |
| MSC | 2 | 3.58e-04 | 5.21e-04 |
| NFATC2 | 2 | 3.58e-04 | 5.21e-04 |
| NR0B1 | 2 | 3.58e-04 | 5.21e-04 |
| SIRT1 | 3 | 3.93e-04 | 5.66e-04 |
| HDAC7 | 2 | 5.06e-04 | 6.97e-04 |
| KAT2B | 2 | 5.90e-04 | 7.93e-04 |
| JUNB | 2 | 6.79e-04 | 8.93e-04 |
| TBX21 | 2 | 6.79e-04 | 8.93e-04 |
| TCF3 | 2 | 6.79e-04 | 8.93e-04 |
| PITX1 | 2 | 7.75e-04 | 9.98e-04 |
| TBP | 2 | 7.75e-04 | 9.98e-04 |
| DDIT3 | 2 | 8.77e-04 | 1.11e-03 |
| FOXM1 | 2 | 9.85e-04 | 1.22e-03 |
| ELK1 | 2 | 1.22e-03 | 1.47e-03 |
| KLF6 | 2 | 1.22e-03 | 1.47e-03 |
| PML | 2 | 1.22e-03 | 1.47e-03 |
| RUNX2 | 2 | 1.22e-03 | 1.47e-03 |
| XBP1 | 2 | 1.22e-03 | 1.47e-03 |
| ARNT | 2 | 1.48e-03 | 1.75e-03 |
| HDAC9 | 2 | 1.48e-03 | 1.75e-03 |
| AHR | 2 | 1.61e-03 | 1.90e-03 |
| CTNNB1 | 2 | 1.61e-03 | 1.90e-03 |
| ATF1 | 2 | 1.76e-03 | 2.05e-03 |
| ETV4 | 2 | 1.76e-03 | 2.05e-03 |
| GATA4 | 2 | 1.76e-03 | 2.05e-03 |
| FLI1 | 2 | 1.91e-03 | 2.21e-03 |
| SOX9 | 2 | 1.91e-03 | 2.21e-03 |
| TWIST2 | 2 | 1.91e-03 | 2.21e-03 |
| YY1 | 3 | 1.99e-03 | 2.29e-03 |
| NR1I2 | 2 | 2.06e-03 | 2.37e-03 |
| POU5F1 | 2 | 2.06e-03 | 2.37e-03 |
| RARA | 2 | 2.23e-03 | 2.54e-03 |
| SMAD4 | 2 | 2.23e-03 | 2.54e-03 |
| TCF4 | 2 | 2.23e-03 | 2.54e-03 |
| ERG | 2 | 2.39e-03 | 2.71e-03 |
| MYC | 3 | 2.85e-03 | 3.16e-03 |
| RB1 | 2 | 2.93e-03 | 3.24e-03 |
| CDX2 | 2 | 3.31e-03 | 3.62e-03 |
| TWIST1 | 2 | 3.94e-03 | 4.26e-03 |
| POU2F1 | 2 | 4.38e-03 | 4.68e-03 |
| GATA3 | 2 | 5.33e-03 | 5.66e-03 |
| E2F1 | 3 | 5.86e-03 | 6.18e-03 |
| PPARG | 2 | 1.39e-02 | 1.41e-02 |
3. Diseases / Pathways associated with VDR
top
- Disease Ontology terms
| # | Description | Term ID | # of overlapped genes | P value | FDR |
|---|
| 1 | Malignant neoplasm of prostate | DOID:10283 | 15 | 2.549e-13 | 6.061e-12 |
| 2 | disease | DOID:4 | 27 | 5.979e-13 | 1.312e-11 |
| 3 | Diabetes Mellitus, Non-Insulin-Dependent | DOID:9352 | 12 | 4.124e-12 | 7.654e-11 |
| 4 | Malignant neoplasm of breast | DOID:4241 | 15 | 8.804e-12 | 1.513e-10 |
| 5 | Malignant neoplasm of lung | DOID:1324 | 11 | 1.134e-11 | 1.900e-10 |
| 6 | Malignant neoplasm of stomach | DOID:10534 | 11 | 1.134e-11 | 1.900e-10 |
| 7 | Malignant Neoplasms | DOID:462 | 15 | 2.564e-10 | 3.191e-09 |
| 8 | Embryoma | DOID:4766 | 13 | 3.029e-10 | 3.692e-09 |
| 9 | Osteosarcoma of Bone | DOID:3376 | 7 | 3.205e-10 | 3.880e-09 |
| 10 | cancer | DOID:162 | 15 | 3.347e-10 | 4.034e-09 |
| 11 | Breast Carcinoma | DOID:3459 | 8 | 4.742e-10 | 5.547e-09 |
| 12 | Osteosarcoma | DOID:3347 | 7 | 6.173e-10 | 7.024e-09 |
| 13 | Advanced Cancer | DOID:2337 | 6 | 7.224e-10 | 8.111e-09 |
| 14 | Melanoma | DOID:1909 | 10 | 7.375e-10 | 8.252e-09 |
| 15 | Carcinoma of the Large Intestine | DOID:1994 | 10 | 1.386e-09 | 1.451e-08 |
| 16 | acute leukemia | DOID:12603 | 6 | 1.609e-09 | 1.658e-08 |
| 17 | Malignant tumor of colon | DOID:219 | 9 | 2.247e-09 | 2.235e-08 |
| 18 | Stomach Carcinoma | DOID:5517 | 7 | 3.700e-09 | 3.488e-08 |
| 19 | Infection | DOID:945 | 9 | 5.030e-09 | 4.601e-08 |
| 20 | Neoplasm Metastasis | DOID:2619 | 10 | 6.747e-09 | 5.970e-08 |
| 21 | Endometrial Carcinoma | DOID:2871 | 7 | 8.515e-09 | 7.367e-08 |
| 22 | Tuberculosis | DOID:399 | 6 | 9.814e-09 | 8.314e-08 |
| 23 | Malignant neoplasm of ovary | DOID:2144 | 8 | 2.007e-08 | 1.556e-07 |
| 24 | Rheumatoid Arthritis | DOID:7148 | 9 | 2.114e-08 | 1.631e-07 |
| 25 | Small cell carcinoma of lung | DOID:5409 | 6 | 3.355e-08 | 2.459e-07 |
| 26 | Endometriosis | DOID:289 | 7 | 3.643e-08 | 2.631e-07 |
| 27 | Squamous cell carcinoma | DOID:1749 | 8 | 4.760e-08 | 3.308e-07 |
| 28 | Cholangiocarcinoma | DOID:4947 | 5 | 4.771e-08 | 3.314e-07 |
| 29 | Esophageal Neoplasms | DOID:5041 | 6 | 5.139e-08 | 3.539e-07 |
| 30 | Hepatitis C, chronic | DOID:2049 | 5 | 5.373e-08 | 3.677e-07 |
| 31 | Renal Cell Carcinoma | DOID:4450 | 7 | 9.347e-08 | 5.989e-07 |
| 32 | Adenocarcinoma | DOID:299 | 7 | 1.295e-07 | 7.970e-07 |
| 33 | Severe acute Respiratory syndrome | DOID:2945 | 4 | 1.455e-07 | 8.795e-07 |
| 34 | Carcinoma of Nasopharynx | DOID:9261 | 5 | 1.538e-07 | 9.247e-07 |
| 35 | Myeloid leukemia, acute | DOID:9119 | 7 | 1.699e-07 | 1.012e-06 |
| 36 | Neuroendocrine Tumors | DOID:169 | 4 | 2.146e-07 | 1.237e-06 |
| 37 | Laryngeal Squamous Cell Carcinoma | DOID:2876 | 4 | 2.570e-07 | 1.454e-06 |
| 38 | Neoplasm, Ovarian | DOID:2394 | 5 | 3.366e-07 | 1.828e-06 |
| 39 | Malignant neoplasm of pancreas | DOID:1793 | 7 | 3.487e-07 | 1.885e-06 |
| 40 | Multiple Sclerosis | DOID:2377 | 6 | 3.979e-07 | 2.106e-06 |
| 41 | Multiple Myeloma | DOID:9538 | 6 | 4.799e-07 | 2.468e-06 |
| 42 | Atherosclerosis | DOID:1936 | 6 | 5.025e-07 | 2.568e-06 |
| 43 | Primary carcinoma of the liver cells | DOID:684 | 8 | 5.241e-07 | 2.664e-06 |
| 44 | Papillary thyroid carcinoma | DOID:3969 | 4 | 8.582e-07 | 4.066e-06 |
| 45 | acoustic neuroma | DOID:12689 | 3 | 9.620e-07 | 4.470e-06 |
| 46 | Subacute sclerosing panencephalitis | DOID:8970 | 3 | 9.620e-07 | 4.470e-06 |
| 47 | Prostatic Neoplasms | DOID:514 | 5 | 1.050e-06 | 4.817e-06 |
| 48 | Primary Tumor | DOID:8176 | 5 | 1.189e-06 | 5.373e-06 |
| 49 | Malignant neoplasm of esophagus | DOID:1104 | 5 | 1.343e-06 | 5.976e-06 |
| 50 | Leukemia | DOID:1240 | 7 | 1.448e-06 | 6.375e-06 |
| 51 | malaria | DOID:12365 | 4 | 1.744e-06 | 7.495e-06 |
| 52 | Osteoporosis | DOID:11476 | 4 | 2.152e-06 | 8.940e-06 |
| 53 | Ulcerative colitis, unspecified | DOID:8577 | 5 | 2.240e-06 | 9.263e-06 |
| 54 | Neck Neoplasms | DOID:4725 | 3 | 2.507e-06 | 1.019e-05 |
| 55 | Malignant neoplasm of thyroid | DOID:10008 | 4 | 2.626e-06 | 1.061e-05 |
| 56 | Prostatic Hypertrophy, Benign | DOID:11131 | 4 | 3.175e-06 | 1.247e-05 |
| 57 | Breast Cancer Stage IV | DOID:6267 | 4 | 3.175e-06 | 1.247e-05 |
| 58 | Squamous Cell Carcinoma of Esophagus | DOID:3748 | 5 | 3.219e-06 | 1.261e-05 |
| 59 | Malignant neoplasm of cervix uteri | DOID:4361 | 5 | 4.103e-06 | 1.546e-05 |
| 60 | HIV Infections | DOID:526 | 5 | 4.719e-06 | 1.741e-05 |
| 61 | Glioma | DOID:2627 | 6 | 4.943e-06 | 1.804e-05 |
| 62 | Myasthenia Gravis | DOID:437 | 3 | 5.161e-06 | 1.870e-05 |
| 63 | Endometriosis of uterus | DOID:288 | 3 | 5.161e-06 | 1.870e-05 |
| 64 | Malignant neoplasm of mouth, unspecified | DOID:8894 | 4 | 5.331e-06 | 1.922e-05 |
| 65 | Malignant Pleural Mesothelioma | DOID:7474 | 3 | 7.687e-06 | 2.618e-05 |
| 66 | Uremia | DOID:4676 | 3 | 9.210e-06 | 3.062e-05 |
| 67 | Systemic lupus erythematosus | DOID:9074 | 5 | 1.090e-05 | 3.527e-05 |
| 68 | Ankylosing spondylitis | DOID:7147 | 3 | 1.092e-05 | 3.528e-05 |
| 69 | Astrocytoma | DOID:3069 | 4 | 1.349e-05 | 4.215e-05 |
| 70 | Anemia | DOID:2355 | 3 | 1.494e-05 | 4.564e-05 |
| 71 | Pancreatitis, relapsing | DOID:13315 | 3 | 1.494e-05 | 4.564e-05 |
| 72 | Polycystic Ovary syndrome | DOID:11612 | 4 | 1.528e-05 | 4.650e-05 |
| 73 | Colon Carcinoma | DOID:1520 | 4 | 1.624e-05 | 4.902e-05 |
| 74 | Pituitary Neoplasms | DOID:1785 | 3 | 1.727e-05 | 5.163e-05 |
| 75 | Liver neoplasms | DOID:3571 | 4 | 1.829e-05 | 5.407e-05 |
| 76 | Coronary Arteriosclerosis | DOID:3363 | 5 | 1.937e-05 | 5.682e-05 |
| 77 | Bone Metastases | DOID:2759 | 3 | 2.262e-05 | 6.477e-05 |
| 78 | Adenocarcinoma of Lung | DOID:3910 | 4 | 2.424e-05 | 6.858e-05 |
| 79 | Asthma | DOID:2841 | 5 | 2.439e-05 | 6.900e-05 |
| 80 | Systemic infection | DOID:2288 | 4 | 2.842e-05 | 7.810e-05 |
| 81 | Lung diseases | DOID:850 | 3 | 2.897e-05 | 7.936e-05 |
| 82 | chronic Obstructive Airway disease | DOID:3083 | 4 | 3.149e-05 | 8.517e-05 |
| 83 | Cervical Squamous Cell Carcinoma | DOID:3744 | 4 | 3.655e-05 | 9.603e-05 |
| 84 | Regional enteritis of unspecified site | DOID:8778 | 4 | 3.655e-05 | 9.603e-05 |
| 85 | Malignant Glioma | DOID:3070 | 5 | 3.741e-05 | 9.787e-05 |
| 86 | Carcinoma | DOID:305 | 5 | 3.741e-05 | 9.787e-05 |
| 87 | Pituitary Adenoma | DOID:3829 | 3 | 4.051e-05 | 1.042e-04 |
| 88 | Gastrointestinal Stromal Tumors | DOID:9253 | 3 | 4.051e-05 | 1.042e-04 |
| 89 | Adenoma | DOID:657 | 4 | 4.626e-05 | 1.164e-04 |
| 90 | Burning Mouth syndrome | DOID:4331 | 2 | 5.203e-05 | 1.280e-04 |
| 91 | viral hepatitis | DOID:1884 | 2 | 5.203e-05 | 1.280e-04 |
| 92 | Metastatic Melanoma | DOID:4358 | 3 | 6.010e-05 | 1.441e-04 |
| 93 | Obesity | DOID:9970 | 5 | 6.142e-05 | 1.464e-04 |
| 94 | Parkinson disease | DOID:14330 | 4 | 6.285e-05 | 1.492e-04 |
| 95 | Celiac disease | DOID:10608 | 3 | 6.581e-05 | 1.545e-04 |
| 96 | Retinoblastoma | DOID:768 | 3 | 6.581e-05 | 1.545e-04 |
| 97 | Malignant neoplasm of urinary bladder | DOID:11054 | 4 | 7.408e-05 | 1.703e-04 |
| 98 | Carcinoma, Large Cell | DOID:4552 | 2 | 7.794e-05 | 1.772e-04 |
| 99 | Malignant neoplasm of tongue, unspecified | DOID:8649 | 2 | 7.794e-05 | 1.772e-04 |
| 100 | Peptic Ulcer | DOID:750 | 2 | 7.794e-05 | 1.772e-04 |
| 101 | Malignant neoplasm of male breast | DOID:9796 | 2 | 7.794e-05 | 1.772e-04 |
| 102 | Mycobacterium Infections | DOID:2757 | 2 | 7.794e-05 | 1.772e-04 |
| 103 | Uterine Fibroids | DOID:13223 | 3 | 7.827e-05 | 1.779e-04 |
| 104 | Malignant neoplasm of liver | DOID:12300 | 3 | 8.504e-05 | 1.905e-04 |
| 105 | Diabetes Mellitus | DOID:9351 | 4 | 8.671e-05 | 1.934e-04 |
| 106 | Metastasis to Lymph Nodes | DOID:10437 | 4 | 9.716e-05 | 2.117e-04 |
| 107 | Lymphoma | DOID:353 | 4 | 9.716e-05 | 2.117e-04 |
| 108 | schizophrenia | DOID:5419 | 5 | 9.819e-05 | 2.137e-04 |
| 109 | Hamman-Rich syndrome | DOID:2797 | 3 | 9.970e-05 | 2.164e-04 |
| 110 | Carcinoma of lung | DOID:3905 | 3 | 9.970e-05 | 2.164e-04 |
| 111 | Glioblastoma | DOID:3068 | 4 | 1.008e-04 | 2.181e-04 |
| 112 | Cervix carcinoma | DOID:2893 | 3 | 1.076e-04 | 2.300e-04 |
| 113 | Cerebral Palsy | DOID:1969 | 2 | 1.090e-04 | 2.322e-04 |
| 114 | Fibromyalgia | DOID:631 | 2 | 1.090e-04 | 2.322e-04 |
| 115 | Testicular dysfunction | DOID:11019 | 3 | 1.433e-04 | 2.914e-04 |
| 116 | End stage renal failure | DOID:783 | 3 | 1.433e-04 | 2.914e-04 |
| 117 | Myeloid leukemia, chronic | DOID:8552 | 3 | 1.433e-04 | 2.914e-04 |
| 118 | Metabolic syndrome X | DOID:14221 | 2 | 1.451e-04 | 2.941e-04 |
| 119 | Infiltrating Malignant Neoplasm | DOID:8062 | 3 | 1.533e-04 | 3.077e-04 |
| 120 | Liver Metastases | DOID:12722 | 3 | 1.637e-04 | 3.243e-04 |
| 121 | Behcet syndrome | DOID:13241 | 3 | 1.746e-04 | 3.421e-04 |
| 122 | HTLV-I Infections | DOID:323 | 2 | 1.862e-04 | 3.605e-04 |
| 123 | Gingivitis | DOID:3087 | 2 | 1.862e-04 | 3.605e-04 |
| 124 | Nevus | DOID:2681 | 2 | 1.862e-04 | 3.605e-04 |
| 125 | Carcinoma, Transitional Cell | DOID:3995 | 3 | 1.978e-04 | 3.780e-04 |
| 126 | Adenocarcinoma of the Pancreas | DOID:4074 | 3 | 2.228e-04 | 4.161e-04 |
| 127 | brucellosis | DOID:11077 | 2 | 2.837e-04 | 5.055e-04 |
| 128 | Metastatic malignant neoplasm to brain | DOID:927 | 2 | 2.837e-04 | 5.055e-04 |
| 129 | Ductal Carcinoma | DOID:3007 | 3 | 2.942e-04 | 5.204e-04 |
| 130 | Essential Hypertension | DOID:10825 | 3 | 3.264e-04 | 5.669e-04 |
| 131 | Rheumatic Heart disease | DOID:9814 | 2 | 3.399e-04 | 5.859e-04 |
| 132 | Bone diseases | DOID:1290 | 2 | 3.399e-04 | 5.859e-04 |
| 133 | Dental Plaque | DOID:13598 | 3 | 3.789e-04 | 6.422e-04 |
| 134 | Ependymoma | DOID:4844 | 2 | 4.011e-04 | 6.715e-04 |
| 135 | Leprosy | DOID:1024 | 2 | 4.011e-04 | 6.715e-04 |
| 136 | Secondary Carcinoma | DOID:4102 | 2 | 4.011e-04 | 6.715e-04 |
| 137 | Temporal Arteritis | DOID:13375 | 2 | 4.011e-04 | 6.715e-04 |
| 138 | Malignant neoplasm of endometrium | DOID:5654 | 3 | 4.365e-04 | 7.193e-04 |
| 139 | Prostate carcinoma | DOID:10286 | 3 | 4.569e-04 | 7.470e-04 |
| 140 | Yersinia infections | DOID:3300 | 3 | 4.569e-04 | 7.470e-04 |
| 141 | Infection of amniotic sac and membranes | DOID:13429 | 2 | 4.673e-04 | 7.605e-04 |
| 142 | Sarcoma, Synovial | DOID:5485 | 2 | 4.673e-04 | 7.605e-04 |
| 143 | Dependence | DOID:9973 | 3 | 5.445e-04 | 8.629e-04 |
| 144 | Bacterial Infections | DOID:104 | 2 | 6.144e-04 | 9.530e-04 |
| 145 | Carcinoma in situ | DOID:8719 | 2 | 6.144e-04 | 9.530e-04 |
| 146 | Aplastic Anemia | DOID:12449 | 2 | 6.953e-04 | 1.055e-03 |
| 147 | Hodgkin's disease, unspecified type | DOID:8567 | 3 | 7.223e-04 | 1.088e-03 |
| 148 | Tuberculosis, Pulmonary | DOID:2957 | 2 | 7.810e-04 | 1.159e-03 |
| 149 | Gallbladder Carcinoma | DOID:4948 | 2 | 7.810e-04 | 1.159e-03 |
| 150 | Malignant neoplasm of gallbladder | DOID:8090 | 2 | 7.810e-04 | 1.159e-03 |
| 151 | Periodontal diseases | DOID:3388 | 2 | 8.716e-04 | 1.269e-03 |
| 152 | Germ cell tumor | DOID:2994 | 2 | 9.670e-04 | 1.381e-03 |
| 153 | Sudden infant death syndrome | DOID:9007 | 2 | 9.670e-04 | 1.381e-03 |
| 154 | Dermatitis, Atopic | DOID:3310 | 3 | 9.665e-04 | 1.381e-03 |
| 155 | Nephroblastoma | DOID:2154 | 2 | 9.670e-04 | 1.381e-03 |
| 156 | Cerebrovascular accident | DOID:3455 | 3 | 1.000e-03 | 1.423e-03 |
| 157 | Cerebral Infarction | DOID:3526 | 2 | 1.067e-03 | 1.501e-03 |
| 158 | Hepatitis | DOID:2237 | 2 | 1.067e-03 | 1.501e-03 |
| 159 | Pancreatitis | DOID:4989 | 2 | 1.067e-03 | 1.501e-03 |
| 160 | Esophageal carcinoma | DOID:1107 | 2 | 1.172e-03 | 1.622e-03 |
| 161 | acute pancreatitis | DOID:2913 | 2 | 1.282e-03 | 1.747e-03 |
| 162 | Sarcoma | DOID:1115 | 2 | 1.282e-03 | 1.747e-03 |
| 163 | Aortic Aneurysm, Abdominal | DOID:7693 | 2 | 1.397e-03 | 1.876e-03 |
| 164 | Malignant mesothelioma | DOID:1790 | 2 | 1.516e-03 | 2.013e-03 |
| 165 | Lupus Vulgaris | DOID:5380 | 2 | 1.640e-03 | 2.151e-03 |
| 166 | Neoplasm, Thyroid | DOID:1781 | 2 | 1.768e-03 | 2.293e-03 |
| 167 | Carcinoma, Papillary | DOID:3113 | 2 | 1.768e-03 | 2.293e-03 |
| 168 | Neoplasms, Epithelial | DOID:157 | 2 | 1.768e-03 | 2.293e-03 |
| 169 | syndrome | DOID:225 | 4 | 1.792e-03 | 2.318e-03 |
| 170 | Lupus erythematosus | DOID:8857 | 2 | 2.182e-03 | 2.747e-03 |
| 171 | Barrett's esophagus | DOID:9206 | 2 | 2.182e-03 | 2.747e-03 |
| 172 | Primary biliary cirrhosis | DOID:12236 | 2 | 2.329e-03 | 2.898e-03 |
| 173 | Liver diseases | DOID:409 | 2 | 2.636e-03 | 3.228e-03 |
| 174 | Adenocarcinoma of Esophagus | DOID:4914 | 2 | 2.797e-03 | 3.401e-03 |
| 175 | Colorectal Neoplasms | DOID:1985 | 2 | 2.797e-03 | 3.401e-03 |
| 176 | IGA Glomerulonephritis | DOID:2986 | 2 | 2.797e-03 | 3.401e-03 |
| 177 | Hypertension induced by pregnancy | DOID:12684 | 3 | 2.949e-03 | 3.560e-03 |
| 178 | Diabetes Mellitus, Insulin-Dependent | DOID:9744 | 2 | 2.962e-03 | 3.575e-03 |
| 179 | Asthma, allergic NOS | DOID:9415 | 2 | 3.132e-03 | 3.755e-03 |
| 180 | Basal cell carcinoma | DOID:2513 | 2 | 3.132e-03 | 3.755e-03 |
| 181 | Sarcoidosis | DOID:11335 | 2 | 3.306e-03 | 3.939e-03 |
| 182 | Stomach Neoplasms | DOID:4713 | 2 | 3.306e-03 | 3.939e-03 |
| 183 | Thyroid carcinoma | DOID:3963 | 2 | 4.047e-03 | 4.708e-03 |
| 184 | Periodontitis | DOID:824 | 2 | 4.243e-03 | 4.910e-03 |
| 185 | Hypertension | DOID:10763 | 3 | 4.575e-03 | 5.251e-03 |
| 186 | Leukemia, Lymphocytic, acute | DOID:9952 | 2 | 4.857e-03 | 5.537e-03 |
| 187 | Cystic Fibrosis | DOID:1485 | 2 | 5.070e-03 | 5.759e-03 |
| 188 | Diabetic Retinopathy | DOID:8947 | 2 | 5.070e-03 | 5.759e-03 |
| 189 | Unspecified myeloid leukemia | DOID:8692 | 2 | 5.736e-03 | 6.431e-03 |
| 190 | Graves' disease | DOID:12361 | 2 | 5.966e-03 | 6.668e-03 |
| 191 | Lung Neoplasms | DOID:3683 | 2 | 6.200e-03 | 6.911e-03 |
| 192 | Infertility | DOID:5223 | 2 | 6.200e-03 | 6.911e-03 |
| 193 | Adenovirus Infections | DOID:3124 | 2 | 7.694e-03 | 8.406e-03 |
| 194 | Coronary heart disease | DOID:3393 | 2 | 8.495e-03 | 9.203e-03 |
| 195 | autoimmune disease | DOID:417 | 2 | 9.910e-03 | 1.062e-02 |
| 196 | Diabetic Nephropathy | DOID:2370 | 2 | 1.050e-02 | 1.123e-02 |
| 197 | Virus diseases | DOID:934 | 2 | 1.270e-02 | 1.340e-02 |
| 198 | Alzheimer's disease | DOID:10652 | 3 | 1.293e-02 | 1.364e-02 |
| 199 | Congenital Abnormality | DOID:759 | 3 | 1.342e-02 | 1.413e-02 |
| 200 | Down syndrome | DOID:14250 | 2 | 1.370e-02 | 1.441e-02 |
| 201 | Degenerative polyarthritis | DOID:455 | 2 | 1.726e-02 | 1.795e-02 |
| 202 | Systemic Scleroderma | DOID:418 | 2 | 1.802e-02 | 1.870e-02 |
| 203 | Leukemia, Lymphocytic, chronic | DOID:1040 | 2 | 2.454e-02 | 2.517e-02 |
| 204 | Pre-Eclampsia | DOID:10591 | 2 | 2.675e-02 | 2.736e-02 |
| 205 | Neuroblastoma | DOID:769 | 2 | 3.045e-02 | 3.102e-02 |
- KEGG pathway/disease terms
| # | Description | Term ID | # of overlapped genes | P value | FDR |
|---|
| 1 | Transcriptional misregulation in cancer | hsa05202 | 9 | 2.780e-10 | 4.583e-09 |
| 2 | Cytokine-cytokine receptor interaction | hsa04060 | 10 | 4.183e-10 | 6.576e-09 |
| 3 | Inflammatory bowel disease (IBD) | hsa05321 | 6 | 8.951e-09 | 1.024e-07 |
| 4 | Bladder cancer | hsa05219 | 5 | 4.223e-08 | 4.025e-07 |
| 5 | Steroid hormone biosynthesis | hsa00140 | 5 | 2.414e-07 | 1.864e-06 |
| 6 | Pathways in cancer | hsa05200 | 9 | 2.714e-07 | 2.075e-06 |
| 7 | FoxO signaling pathway | hsa04068 | 6 | 6.567e-07 | 4.470e-06 |
| 8 | Pertussis | hsa05133 | 5 | 8.650e-07 | 5.656e-06 |
| 9 | PI3K-Akt signaling pathway | hsa04151 | 8 | 1.141e-06 | 7.128e-06 |
| 10 | Jak-STAT signaling pathway | hsa04630 | 6 | 1.711e-06 | 1.007e-05 |
| 11 | Allograft rejection | hsa05330 | 4 | 1.744e-06 | 1.022e-05 |
| 12 | Tuberculosis | hsa05152 | 6 | 3.292e-06 | 1.738e-05 |
| 13 | HIF-1 signaling pathway | hsa04066 | 5 | 4.103e-06 | 2.094e-05 |
| 14 | Chagas disease (American trypanosomiasis) | hsa05142 | 5 | 4.301e-06 | 2.177e-05 |
| 15 | Intestinal immune network for IgA production | hsa04672 | 4 | 4.520e-06 | 2.267e-05 |
| 16 | Toll-like receptor signaling pathway | hsa04620 | 5 | 4.719e-06 | 2.354e-05 |
| 17 | Amoebiasis | hsa05146 | 5 | 5.168e-06 | 2.542e-05 |
| 18 | Legionellosis | hsa05134 | 4 | 8.417e-06 | 3.870e-05 |
| 19 | Retinol metabolism | hsa00830 | 4 | 1.624e-05 | 6.765e-05 |
| 20 | Chemical carcinogenesis | hsa05204 | 4 | 3.836e-05 | 1.388e-04 |
| 21 | ErbB signaling pathway | hsa04012 | 4 | 5.062e-05 | 1.752e-04 |
| 22 | Prostate cancer | hsa05215 | 4 | 5.528e-05 | 1.892e-04 |
| 23 | Rheumatoid arthritis | hsa05323 | 4 | 5.528e-05 | 1.892e-04 |
| 24 | MicroRNAs in cancer | hsa05206 | 6 | 6.096e-05 | 2.056e-04 |
| 25 | African trypanosomiasis | hsa05143 | 3 | 7.186e-05 | 2.364e-04 |
| 26 | Epstein-Barr virus infection | hsa05169 | 5 | 9.819e-05 | 3.055e-04 |
| 27 | Graft-versus-host disease | hsa05332 | 3 | 1.246e-04 | 3.687e-04 |
| 28 | Type I diabetes mellitus | hsa04940 | 3 | 1.433e-04 | 4.114e-04 |
| 29 | Malaria | hsa05144 | 3 | 2.100e-04 | 5.587e-04 |
| 30 | Autoimmune thyroid disease | hsa05320 | 3 | 2.498e-04 | 6.412e-04 |
| 31 | Endometrial cancer | hsa05213 | 3 | 2.498e-04 | 6.412e-04 |
| 32 | Measles | hsa05162 | 4 | 2.654e-04 | 6.687e-04 |
| 33 | Hepatitis B | hsa05161 | 4 | 3.669e-04 | 8.625e-04 |
| 34 | Pancreatic cancer | hsa05212 | 3 | 4.994e-04 | 1.104e-03 |
| 35 | Melanoma | hsa05218 | 3 | 6.168e-04 | 1.305e-03 |
| 36 | Leishmaniasis | hsa05140 | 3 | 6.422e-04 | 1.351e-03 |
| 37 | Adherens junction | hsa04520 | 3 | 6.682e-04 | 1.396e-03 |
| 38 | Metabolism of xenobiotics by cytochrome P450 | hsa00980 | 3 | 6.949e-04 | 1.439e-03 |
| 39 | Influenza A | hsa05164 | 4 | 7.230e-04 | 1.483e-03 |
| 40 | Herpes simplex infection | hsa05168 | 4 | 8.708e-04 | 1.720e-03 |
| 41 | Salmonella infection | hsa05132 | 3 | 1.070e-03 | 2.026e-03 |
| 42 | Hematopoietic cell lineage | hsa04640 | 3 | 1.106e-03 | 2.084e-03 |
| 43 | Salivary secretion | hsa04970 | 3 | 1.180e-03 | 2.193e-03 |
| 44 | Proteoglycans in cancer | hsa05205 | 4 | 1.251e-03 | 2.292e-03 |
| 45 | NF-kappa B signaling pathway | hsa04064 | 3 | 1.257e-03 | 2.302e-03 |
| 46 | Asthma | hsa05310 | 2 | 2.329e-03 | 3.781e-03 |
| 47 | Toxoplasmosis | hsa05145 | 3 | 2.625e-03 | 4.162e-03 |
| 48 | HTLV-I infection | hsa05166 | 4 | 2.982e-03 | 4.610e-03 |
| 49 | Cell cycle | hsa04110 | 3 | 3.017e-03 | 4.653e-03 |
| 50 | Hepatitis C | hsa05160 | 3 | 3.669e-03 | 5.455e-03 |
| 51 | Phospholipase D signaling pathway | hsa04072 | 3 | 4.488e-03 | 6.426e-03 |
| 52 | Staphylococcus aureus infection | hsa05150 | 2 | 7.435e-03 | 9.858e-03 |
| 53 | Pathogenic Escherichia coli infection | hsa05130 | 2 | 7.435e-03 | 9.858e-03 |
| 54 | Non-small cell lung cancer | hsa05223 | 2 | 7.694e-03 | 1.013e-02 |
| 55 | NOD-like receptor signaling pathway | hsa04621 | 2 | 7.957e-03 | 1.043e-02 |
| 56 | Glioma | hsa05214 | 2 | 1.020e-02 | 1.292e-02 |
| 57 | Central carbon metabolism in cancer | hsa05230 | 2 | 1.081e-02 | 1.356e-02 |
| 58 | Drug metabolism - cytochrome P450 | hsa00982 | 2 | 1.111e-02 | 1.390e-02 |
| 59 | p53 signaling pathway | hsa04115 | 2 | 1.111e-02 | 1.390e-02 |
| 60 | Epithelial cell signaling in Helicobacter pylori infection | hsa05120 | 2 | 1.111e-02 | 1.390e-02 |
| 61 | PPAR signaling pathway | hsa03320 | 2 | 1.142e-02 | 1.422e-02 |
| 62 | RIG-I-like receptor signaling pathway | hsa04622 | 2 | 1.174e-02 | 1.458e-02 |
| 63 | Viral carcinogenesis | hsa05203 | 3 | 1.197e-02 | 1.483e-02 |
| 64 | Bile secretion | hsa04976 | 2 | 1.205e-02 | 1.491e-02 |
| 65 | Focal adhesion | hsa04510 | 3 | 1.229e-02 | 1.517e-02 |
| 66 | Prolactin signaling pathway | hsa04917 | 2 | 1.238e-02 | 1.526e-02 |
| 67 | Chronic myeloid leukemia | hsa05220 | 2 | 1.270e-02 | 1.562e-02 |
| 68 | Small cell lung cancer | hsa05222 | 2 | 1.726e-02 | 2.046e-02 |
| 69 | GnRH signaling pathway | hsa04912 | 2 | 1.917e-02 | 2.245e-02 |
| 70 | Fc gamma R-mediated phagocytosis | hsa04666 | 2 | 1.957e-02 | 2.286e-02 |
| 71 | Endocytosis | hsa04144 | 3 | 2.193e-02 | 2.534e-02 |
| 72 | Metabolic pathways | hsa01100 | 7 | 2.203e-02 | 2.545e-02 |
| 73 | Choline metabolism in cancer | hsa05231 | 2 | 2.325e-02 | 2.671e-02 |
| 74 | T cell receptor signaling pathway | hsa04660 | 2 | 2.454e-02 | 2.802e-02 |
| 75 | Systemic lupus erythematosus | hsa05322 | 2 | 3.892e-02 | 4.277e-02 |
| 76 | Wnt signaling pathway | hsa04310 | 2 | 4.265e-02 | 4.654e-02 |
| 77 | Cell adhesion molecules (CAMs) | hsa04514 | 2 | 4.319e-02 | 4.709e-02 |
- Gene Ontology biological process terms
| # | Description | Term ID | # of overlapped genes | P value | FDR |
|---|
| 1 | response to drug | GO:0042493 | 8 | 2.569e-07 | 4.743e-06 |
| 2 | xenobiotic metabolic process | GO:0006805 | 6 | 7.160e-07 | 1.084e-05 |
| 3 | vitamin D metabolic process | GO:0042359 | 3 | 1.372e-06 | 1.794e-05 |
| 4 | osteoblast differentiation | GO:0001649 | 4 | 1.940e-06 | 2.325e-05 |
| 5 | cellular response to lipopolysaccharide | GO:0071222 | 4 | 2.891e-06 | 3.158e-05 |
| 6 | defense response to Gram-negative bacterium | GO:0050829 | 3 | 5.161e-06 | 4.892e-05 |
| 7 | negative regulation of growth of symbiont in host | GO:0044130 | 3 | 5.161e-06 | 4.892e-05 |
| 8 | response to vitamin D | GO:0033280 | 3 | 7.687e-06 | 6.561e-05 |
| 9 | negative regulation of cell proliferation | GO:0008285 | 7 | 1.082e-05 | 8.492e-05 |
| 10 | ossification | GO:0001503 | 4 | 1.624e-05 | 1.150e-04 |
| 11 | positive regulation of phosphorylation | GO:0042327 | 3 | 2.262e-05 | 1.462e-04 |
| 12 | inflammatory response | GO:0006954 | 6 | 2.445e-05 | 1.549e-04 |
| 13 | defense response to Gram-positive bacterium | GO:0050830 | 3 | 4.494e-05 | 2.388e-04 |
| 14 | positive regulation of MAP kinase activity | GO:0043406 | 3 | 4.968e-05 | 2.569e-04 |
| 15 | negative regulation of interleukin-10 production | GO:0032693 | 2 | 5.203e-05 | 2.642e-04 |
| 16 | positive regulation of tissue remodeling | GO:0034105 | 2 | 7.794e-05 | 3.501e-04 |
| 17 | positive regulation of transcription, DNA-dependent | GO:0045893 | 7 | 8.899e-05 | 3.848e-04 |
| 18 | response to organic cyclic compound | GO:0014070 | 4 | 9.010e-05 | 3.890e-04 |
| 19 | G1 phase of mitotic cell cycle | GO:0000080 | 3 | 9.970e-05 | 4.185e-04 |
| 20 | positive regulation of immunoglobulin secretion | GO:0051024 | 2 | 1.090e-04 | 4.466e-04 |
| 21 | response to molecule of bacterial origin | GO:0002237 | 2 | 1.090e-04 | 4.466e-04 |
| 22 | positive regulation of epithelial cell proliferation | GO:0050679 | 3 | 1.533e-04 | 5.649e-04 |
| 23 | positive regulation of protein kinase B signaling cascade | GO:0051897 | 3 | 1.637e-04 | 5.915e-04 |
| 24 | defense response to protozoan | GO:0042832 | 2 | 1.862e-04 | 6.465e-04 |
| 25 | oxidative demethylation | GO:0070989 | 2 | 1.862e-04 | 6.465e-04 |
| 26 | negative regulation of cell-cell adhesion | GO:0022408 | 2 | 1.862e-04 | 6.465e-04 |
| 27 | cell cycle arrest | GO:0007050 | 4 | 2.297e-04 | 7.484e-04 |
| 28 | response to arsenic-containing substance | GO:0046685 | 2 | 2.324e-04 | 7.555e-04 |
| 29 | cholesterol homeostasis | GO:0042632 | 3 | 2.361e-04 | 7.643e-04 |
| 30 | cellular lipid metabolic process | GO:0044255 | 4 | 2.654e-04 | 8.341e-04 |
| 31 | positive regulation of interleukin-17 production | GO:0032740 | 2 | 2.837e-04 | 8.742e-04 |
| 32 | positive regulation of bone resorption | GO:0045780 | 2 | 2.837e-04 | 8.742e-04 |
| 33 | circadian regulation of gene expression | GO:0032922 | 2 | 2.837e-04 | 8.742e-04 |
| 34 | positive regulation of transcription from RNA polymerase II promoter | GO:0045944 | 7 | 3.177e-04 | 9.459e-04 |
| 35 | negative regulation of apoptotic process | GO:0043066 | 5 | 3.193e-04 | 9.496e-04 |
| 36 | negative regulation of cytokine secretion | GO:0050710 | 2 | 3.399e-04 | 9.948e-04 |
| 37 | bone remodeling | GO:0046849 | 2 | 3.399e-04 | 9.948e-04 |
| 38 | negative regulation of interferon-gamma production | GO:0032689 | 2 | 4.011e-04 | 1.119e-03 |
| 39 | monocyte chemotaxis | GO:0002548 | 2 | 4.011e-04 | 1.119e-03 |
| 40 | small molecule metabolic process | GO:0044281 | 9 | 4.580e-04 | 1.232e-03 |
| 41 | negative regulation of interleukin-6 production | GO:0032715 | 2 | 4.673e-04 | 1.249e-03 |
| 42 | positive regulation of osteoclast differentiation | GO:0045672 | 2 | 4.673e-04 | 1.249e-03 |
| 43 | positive regulation of sequence-specific DNA binding transcription factor activity | GO:0051091 | 3 | 4.994e-04 | 1.313e-03 |
| 44 | natural killer cell activation | GO:0030101 | 2 | 5.384e-04 | 1.389e-03 |
| 45 | cell surface receptor signaling pathway | GO:0007166 | 4 | 5.676e-04 | 1.441e-03 |
| 46 | positive regulation of tyrosine phosphorylation of Stat5 protein | GO:0042523 | 2 | 6.144e-04 | 1.521e-03 |
| 47 | positive regulation of JAK-STAT cascade | GO:0046427 | 2 | 6.144e-04 | 1.521e-03 |
| 48 | osteoblast development | GO:0002076 | 2 | 6.144e-04 | 1.521e-03 |
| 49 | cellular response to lithium ion | GO:0071285 | 2 | 6.144e-04 | 1.521e-03 |
| 50 | negative regulation of cyclin-dependent protein kinase activity | GO:0045736 | 2 | 6.953e-04 | 1.669e-03 |
| 51 | cell proliferation | GO:0008283 | 5 | 7.127e-04 | 1.697e-03 |
| 52 | positive regulation of activated T cell proliferation | GO:0042104 | 2 | 8.716e-04 | 1.967e-03 |
| 53 | response to hyperoxia | GO:0055093 | 2 | 8.716e-04 | 1.967e-03 |
| 54 | response to glucocorticoid stimulus | GO:0051384 | 3 | 9.012e-04 | 2.016e-03 |
| 55 | drug metabolic process | GO:0017144 | 2 | 9.670e-04 | 2.120e-03 |
| 56 | positive regulation of cytokine secretion | GO:0050715 | 2 | 1.067e-03 | 2.292e-03 |
| 57 | negative regulation of T cell proliferation | GO:0042130 | 2 | 1.067e-03 | 2.292e-03 |
| 58 | steroid metabolic process | GO:0008202 | 3 | 1.143e-03 | 2.405e-03 |
| 59 | negative regulation of tumor necrosis factor production | GO:0032720 | 2 | 1.172e-03 | 2.451e-03 |
| 60 | cerebellum development | GO:0021549 | 2 | 1.172e-03 | 2.451e-03 |
| 61 | regulation of angiogenesis | GO:0045765 | 2 | 1.172e-03 | 2.451e-03 |
| 62 | negative regulation of smooth muscle cell proliferation | GO:0048662 | 2 | 1.172e-03 | 2.451e-03 |
| 63 | response to steroid hormone stimulus | GO:0048545 | 2 | 1.172e-03 | 2.451e-03 |
| 64 | positive regulation of cell proliferation | GO:0008284 | 5 | 1.324e-03 | 2.687e-03 |
| 65 | positive regulation of NF-kappaB transcription factor activity | GO:0051092 | 3 | 1.379e-03 | 2.776e-03 |
| 66 | regulation of multicellular organism growth | GO:0040014 | 2 | 1.397e-03 | 2.801e-03 |
| 67 | positive regulation of tyrosine phosphorylation of Stat3 protein | GO:0042517 | 2 | 1.397e-03 | 2.801e-03 |
| 68 | immune response | GO:0006955 | 5 | 1.478e-03 | 2.927e-03 |
| 69 | negative regulation of phosphorylation | GO:0042326 | 2 | 1.516e-03 | 2.980e-03 |
| 70 | positive regulation of cell migration | GO:0030335 | 3 | 1.692e-03 | 3.240e-03 |
| 71 | negative regulation of protein phosphorylation | GO:0001933 | 2 | 1.901e-03 | 3.539e-03 |
| 72 | response to antibiotic | GO:0046677 | 2 | 1.901e-03 | 3.539e-03 |
| 73 | positive regulation of mesenchymal cell proliferation | GO:0002053 | 2 | 2.039e-03 | 3.729e-03 |
| 74 | negative regulation of cell growth | GO:0030308 | 3 | 2.154e-03 | 3.893e-03 |
| 75 | positive regulation of tumor necrosis factor production | GO:0032760 | 2 | 2.182e-03 | 3.930e-03 |
| 76 | positive regulation of cell adhesion | GO:0045785 | 2 | 2.182e-03 | 3.930e-03 |
| 77 | response to activity | GO:0014823 | 2 | 2.182e-03 | 3.930e-03 |
| 78 | S phase of mitotic cell cycle | GO:0000084 | 3 | 2.210e-03 | 3.970e-03 |
| 79 | cell-cell signaling | GO:0007267 | 4 | 2.300e-03 | 4.084e-03 |
| 80 | positive regulation of nitric oxide biosynthetic process | GO:0045429 | 2 | 2.329e-03 | 4.119e-03 |
| 81 | response to nutrient levels | GO:0031667 | 2 | 2.480e-03 | 4.332e-03 |
| 82 | positive regulation of B cell proliferation | GO:0030890 | 2 | 2.797e-03 | 4.761e-03 |
| 83 | positive regulation of DNA replication | GO:0045740 | 2 | 2.797e-03 | 4.761e-03 |
| 84 | positive regulation of translation | GO:0045727 | 2 | 2.797e-03 | 4.761e-03 |
| 85 | camera-type eye development | GO:0043010 | 2 | 2.962e-03 | 4.978e-03 |
| 86 | embryonic limb morphogenesis | GO:0030326 | 2 | 3.306e-03 | 5.432e-03 |
| 87 | phosphorylation | GO:0016310 | 2 | 3.306e-03 | 5.432e-03 |
| 88 | skeletal system development | GO:0001501 | 3 | 3.369e-03 | 5.521e-03 |
| 89 | epidermal growth factor receptor signaling pathway | GO:0007173 | 3 | 3.369e-03 | 5.521e-03 |
| 90 | positive regulation of inflammatory response | GO:0050729 | 2 | 3.485e-03 | 5.644e-03 |
| 91 | positive regulation of T cell proliferation | GO:0042102 | 2 | 3.668e-03 | 5.877e-03 |
| 92 | positive regulation of anti-apoptosis | GO:0045768 | 2 | 3.668e-03 | 5.877e-03 |
| 93 | positive regulation of fibroblast proliferation | GO:0048146 | 2 | 3.668e-03 | 5.877e-03 |
| 94 | oxidation-reduction process | GO:0055114 | 3 | 3.746e-03 | 5.982e-03 |
| 95 | negative regulation of inflammatory response | GO:0050728 | 2 | 4.047e-03 | 6.365e-03 |
| 96 | regulation of gene expression | GO:0010468 | 2 | 4.047e-03 | 6.365e-03 |
| 97 | response to organic substance | GO:0010033 | 2 | 4.243e-03 | 6.613e-03 |
| 98 | T cell activation | GO:0042110 | 2 | 4.243e-03 | 6.613e-03 |
| 99 | response to virus | GO:0009615 | 3 | 4.488e-03 | 6.917e-03 |
| 100 | G1/S transition of mitotic cell cycle | GO:0000082 | 3 | 4.575e-03 | 7.024e-03 |
| 101 | skeletal muscle tissue development | GO:0007519 | 2 | 4.857e-03 | 7.363e-03 |
| 102 | response to mechanical stimulus | GO:0009612 | 2 | 4.857e-03 | 7.363e-03 |
| 103 | defense response to virus | GO:0051607 | 2 | 5.510e-03 | 8.138e-03 |
| 104 | response to heat | GO:0009408 | 2 | 5.736e-03 | 8.419e-03 |
| 105 | response to stress | GO:0006950 | 3 | 6.436e-03 | 9.261e-03 |
| 106 | regulation of cyclin-dependent protein kinase activity | GO:0000079 | 2 | 6.682e-03 | 9.555e-03 |
| 107 | negative regulation of sequence-specific DNA binding transcription factor activity | GO:0043433 | 2 | 6.929e-03 | 9.852e-03 |
| 108 | positive regulation of cell growth | GO:0030307 | 2 | 7.957e-03 | 1.103e-02 |
| 109 | positive regulation of MAPK cascade | GO:0043410 | 2 | 7.957e-03 | 1.103e-02 |
| 110 | response to insulin stimulus | GO:0032868 | 2 | 8.495e-03 | 1.163e-02 |
| 111 | neuron projection development | GO:0031175 | 2 | 8.770e-03 | 1.195e-02 |
| 112 | transmembrane receptor protein tyrosine kinase signaling pathway | GO:0007169 | 2 | 9.332e-03 | 1.261e-02 |
| 113 | cellular calcium ion homeostasis | GO:0006874 | 2 | 9.910e-03 | 1.325e-02 |
| 114 | regulation of apoptotic process | GO:0042981 | 3 | 1.033e-02 | 1.372e-02 |
| 115 | DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest | GO:0006977 | 2 | 1.050e-02 | 1.394e-02 |
| 116 | response to toxin | GO:0009636 | 2 | 1.081e-02 | 1.428e-02 |
| 117 | anti-apoptosis | GO:0006916 | 3 | 1.121e-02 | 1.472e-02 |
| 118 | Ras protein signal transduction | GO:0007265 | 2 | 1.174e-02 | 1.531e-02 |
| 119 | phosphatidylinositol-mediated signaling | GO:0048015 | 2 | 1.270e-02 | 1.639e-02 |
| 120 | cell-cell adhesion | GO:0016337 | 2 | 1.270e-02 | 1.639e-02 |
| 121 | negative regulation of transcription, DNA-dependent | GO:0045892 | 4 | 1.273e-02 | 1.642e-02 |
| 122 | calcium ion transport | GO:0006816 | 2 | 1.438e-02 | 1.824e-02 |
| 123 | cytokine-mediated signaling pathway | GO:0019221 | 3 | 1.480e-02 | 1.867e-02 |
| 124 | negative regulation of transcription from RNA polymerase II promoter | GO:0000122 | 4 | 1.564e-02 | 1.961e-02 |
| 125 | positive regulation of protein phosphorylation | GO:0001934 | 2 | 1.579e-02 | 1.978e-02 |
| 126 | T cell receptor signaling pathway | GO:0050852 | 2 | 1.615e-02 | 2.018e-02 |
| 127 | anterior/posterior pattern specification | GO:0009952 | 2 | 1.802e-02 | 2.219e-02 |
| 128 | defense response to bacterium | GO:0042742 | 2 | 1.996e-02 | 2.424e-02 |
| 129 | cell migration | GO:0016477 | 2 | 2.368e-02 | 2.820e-02 |
| 130 | aging | GO:0007568 | 2 | 2.541e-02 | 3.004e-02 |
| 131 | G2/M transition of mitotic cell cycle | GO:0000086 | 2 | 2.904e-02 | 3.389e-02 |
| 132 | chemotaxis | GO:0006935 | 2 | 3.384e-02 | 3.888e-02 |
| 133 | response to lipopolysaccharide | GO:0032496 | 2 | 3.533e-02 | 4.043e-02 |
| 134 | cell cycle checkpoint | GO:0000075 | 2 | 3.635e-02 | 4.149e-02 |
| 135 | mitotic cell cycle | GO:0000278 | 3 | 3.704e-02 | 4.221e-02 |
| 136 | cell adhesion | GO:0007155 | 4 | 3.908e-02 | 4.431e-02 |
